Immunomodulatory treatment of multiple sclerosis in Denmark: A prospective nationwide survey

Multiple Sclerosis

Volumn 12, Issue 3, 2006, Pages 253-264

  Sorensen, Per Soelberg ^a   Koch Henriksen, Nils ^a,b   Ravnborg, Mads ^a   Frederiksen, Jette Lautrup ^c   Jensen, Kai ^d   Heltberg, Anne ^e   Schaldemose, Hanne ^f   Deth, Sven ^g   Kristensen, Ole ^h   Worm, Mogens ⁱ   Stenager, Egon ^j,n   Hansen, Hans Jacob ^k   Sivertsen, Bjarne ^l   Torring, Jesper ^m  

^a Mental Health Services CPH   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d HILLERØD HOSPITAL   (Denmark)

^e ROSKILDE HOSPITAL   (Denmark)

^f HOLBÆK HOSPITAL   (Denmark)

^g NAESTVED HOSPITAL   (Denmark)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ Anæstesiologisk Center   (Denmark)

^j Esbjerg University Hospital   (Denmark)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

^l VIBORG HOSPITAL   (Denmark)

^m HOLSTEBRO HOSPITAL   (Denmark)

ⁿ LILLEBAELT HOSPITAL   (Denmark)

more..

Author keywords

Adverse effects; Epidemiology; Immunotherapy; Interferon beta; Multiple sclerosis; Treatment outcome

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DENMARK; DRUG CHOICE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEALTH SURVEY; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PATIENT COMPLIANCE; PREDICTION; PROPORTIONAL HAZARDS MODEL; REGISTER; RELAPSE; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; BIOLOGICAL RESPONSE MODIFIERS; DATA COLLECTION; DENMARK; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LIFE TABLES; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; TREATMENT OUTCOME;

EID: 33744808980     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1323oa     Document Type: Article

References (20)

1. Koch-Henriksen N, Sorensen PS. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. Mult Scler 2000; 6: 172-75.
2. Koch-Henriksen N, Sorensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006: Epub ahead of print.
3. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brown-Scheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
4. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001; 357: 1576-82.
5. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
6. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-69.
7. Ruggieri RM, Settipani N, Viviano L, Attanasio M, Giglia L, Almasio P et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003; 24: 361-64.
8. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005; 12: 425-31.
9. Milanese C, la Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in dropouts and treated patients. J Neurol Neurosurg Psychiatry 2003; 74: 1689-92.
10. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
11. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group [see comments]. Neurology 1995; 45: 1268-76.
12. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
13. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
14. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
15. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.
16. Khan OA, Tselis AC, Kamholz JA, Garbern JV, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 2001; 7: 349-53.
17. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol 2001; 8: 141-48.
18. Flechter S, Vardi J, Pollak L, Rabey JM. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci 2002; 197: 51-55.
19. Paolillo A, Pozzilli C, Giugni E, Tomassini V, Gasperini C, Morelli M et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. Eur J Neurol 2002; 9: 645-55.
20. Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 2003; 9: 451-57.